CNTX – context therapeutics inc. (US:NASDAQ)

News

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results [Yahoo! Finance]
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Context Therapeutics to Participate in Upcoming Investor Conferences in November
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com